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by age, i.e., children and adolescents (Group A: 5–19) and adults
(Group B: 20+) and compared against an age matched control
group (Group C) (n = 10,2 million). Hospital admissions, out-
patient clinic visits, total nursing days, average length of stay
(ALOS), total hospital and specialist costs were analysed. Data
for the Control group (C) were based on 2001. Data are pre-
sented as a three-year average or otherwise speciﬁed. RESULTS:
The average number of hospital admissions and total nursing
days were; 434(A), 455(B), and 3159(A), 3691(B) respectively.
ALOS (days) were 7.3(A) and 5.3(C). In total there were
8696(A), 2680(B) outpatient clinic visits. Age matched controls
for category (A) had 88,134 days. Males (MPH group) account
for 78% of the total hospital admissions and 86% of outpatient
clinic visits. Sixty percent of the outpatient visits in MPH cate-
gory (A) occurred in age group 10–14, but 26% in age-matched
controls. Total hospital costs were 2800 M€ (A), 2840 M€ (B)
and 47,640 M€ (C) respectively. Specialist costs involved were
0.743 M€ (A), 0.344 M€ (B) and 7750 M€ for 5–19 years (C).
For the MPH group 21% and 28% of these costs were attrib-
uted to patients aged 5–19 years. Nearly 80% of the specialist
and hospital costs were dedicated to males. Average per patient
hospital costs were 258€(A) and 176€(C). CONCLUSIONS: The
data presented here show that ADHD patients have a substan-
tial health care consumption and related health care costs.
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OBJECTIVES: To determine the cost utility of medical co-pre-
scription of heroin compared with methadone maintenance
treatment for chronic, treatment resistant heroin addicts.
METHODS: In a Dutch multicenter study, 430 patients were
randomly assigned to a 1-year maintenance treatment with
methadone (maximum 150mg per day) or with methadone in
combination with inhalable or injectable heroin (maximum 1000
mg per day). Psychosocial treatment was offered throughout.
The primary outcome measures were the one-year costs from a
societal perspective and the number of quality adjusted life years
(QALYs) based on responses to the EQ-5D at baseline and at
various times during the treatment period. The incremental costs
per QALY ratio was calculated along with its 95% bootstrapped
conﬁdence interval. RESULTS: Co-prescription of heroin gener-
ated 0.058 (95% CI: 0.017–0.100) more QALYs on average than
treatment with methadone alone. Mean cost differences between
coprescribed heroin treatment and standard methadone treat-
ment resulted from the maintenance programme itself (17,634€
vs. 1412€ euro), law enforcement (8756 v 12,885 euro), damage
to victims (9617€ vs. 34,991€), and travel (600€ vs. 146€). The
mean total net costs resulting from co-prescribed heroin treat-
ment amounted to minus 12,793 (95% CI: -1049 to -25,169)€.
The incremental cost per QALY was minus 220,569 (95% CI: -
12,252 to -873,193)€. The cost acceptability of co-prescription
of heroin was more than 98.5% for willingness to pay values up
to 50,000€ per additional QALY. The probability of heroin co-
prescription being cost-effective for patients who were illegally
inactive at baseline was below 42%. The results were robust for
the exclusion of the initial implementation costs of heroin treat-
ment. CONCLUSIONS: Co-prescription of heroin is cost-
effective compared with treatment with methadone alone, even
in disregard of the intangible costs of victims of crime.
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OBJECTIVES: The total cost of care (TC) for children with cere-
bral palsy (CP) who use botulinum toxin type A (BTX-A) was
compared to the TC for CP children not using BTX-A.
METHODS: A nested case control design compared BTX-A users
and non-users in the South Carolina Medicaid program from
1995 through 2001. Patients with at least one CP diagnosis
between 1996 and 1999 who were age 18 or younger were
included. They were followed for one year prior to study enroll-
ment, and 24 months after enrollment. A 1 :6 match of BTX-A
users to CP patients (non-BTX-A users) was performed using
propensity scores from a logistic regression model predicting
BTX-A use with demographics, CP severity, analgesia use, inpa-
tient hospitizations, Chronic Disease Score, CP comorbidities,
and pre-period TC. Cases and controls were compared using
logistic regression on post-period data to estimate the same model
predicting BTX-A use. RESULTS: BTX-A users (n = 58) were
identiﬁed and matched to 348 randomly selected non-users. After
matching, the cases and controls were not statistically different
on any of the model variables used in the matching procedure.
Estimation of the ﬁnal model revealed that only CP severity was
signiﬁcantly related to BTX-A use (diplegia p = 0.0107, hemi-
plegia p < 0.0001, and quadraplegia p < 0.001). The Hazard Ratio
for these variables revealed the likelihood of BTX-A use relative
to the lowest CP severity level (diplegia HR = 5.91, hemiplegia
HR = 23.88, and quadraplegia HR = 10.22). While BTX-A is
most frequently used in more severe patients, a statistically sig-
niﬁcant difference in total cost of care was not found (p = 0.528).
CONCLUSIONS: While a greater percentage of CP children
treated with BTX-A had more severe diagnoses, their TC was not
different from CP children not using BTX-A after controlling for
prior-period conditions using propensity scores.
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OBJECTIVES: To evaluate the cost-effectiveness of the ﬁrst long-
acting atypical anti-psychotic injection (risperidone long-acting
injection), compared to a weighted comparator of oral risperi-
done, oral olanzapine and typical depot injections for the man-
agement of patients with schizophrenia, who are partially
adherent to their medication in the specialized public psychiatry
setting. The perspective of the analysis was the Australian health
care system. METHODS: A 1-year decision analytic model was
developed using probabilistic sensitivity analysis to explore
uncertainty. The outcomes used in the cost-effectiveness analysis
(CEA) were relapses avoided, deaths due to suicide averted and
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quality adjusted life years (QALY) gained. Resource utilization
focused on both cost of hospitalization and other community-
care costs such as pharmaceuticals and outpatient consultations.
Clinical trial data and other epidemiological literature were used
to elicit the event probabilities in the decision analytic model.
Utilities for each of the possible health states in the model were
derived from the Australian general population using the Assess-
ment Quality of Life (AQOL) utility instrument. RESULTS:
Against the weighted comparator risperidone long-acting injec-
tion was dominant. Analysis versus oral risperidone and oral
olanzapine also showed that risperidone long-acting injection
was dominant. The incremental cost-effectiveness ratio (ICER)
against typical depots produced a less favourable result due to
the low acquisition cost of these agents. Probabilistic sensitivity
analyses showed a 100% likelihood of an ICER of less than
$50,000 per QALY. CONCLUSIONS: Risperidone long-acting
injection represents a cost-effective intervention for patients who
are partially adherent to their medication. The model indicates
that introduction of risperidone long-acting injection in Australia
will result in signiﬁcant clinical and economic beneﬁts to the
community as partial adherence to medication is a major reason
for relapse of symptoms in patients with schizophrenia.
MENTAL HEALTH
MENTAL HEALTH—Quality of Life/Utility/Preference
Studies
PMH19
THE PERCEIVED BENEFITS OF DOSING SCHEDULES FOR
CHILDREN WITH ADHD
Price M1, Lloyd A2,Yuen C1, Dewilde S2,Annemans L3, Coghill D4
1Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 2MEDTAP
International, London, UK; 3HEDM, Meise, Belgium; 4University of
Dundee, UK
OBJECTIVES: Parents of children with attention deﬁcit hyper-
activity disorder (ADHD) report problems with the need to take
medication three times per day. These problems include storage
and administration of a controlled substance at school and the
stigmatising impact on the child. The present study was designed
to estimate the utility gain associated with switching to a once
per day sustained release (OROS) treatment. METHODS: Clin-
ical data from OROS methylphenidate trials were used to deﬁne
health states associated with monotherapy and combination
therapy (addition of behavioural therapy). To determine the
utility gain with once daily therapy, the monotherapy and com-
bination therapy health states were further distinguished to
specify frequency of dosing. Forty-two interviews with parents
of children with ADHD were conducted where parents were
asked to rate the health states using a visual analogue scale (VAS)
and standard gamble (SG). RESULTS: The 1 per-day treatment
was given a higher valuation with the VAS ratings being 66.3
(±6.6) for the sustained release formulation and 51.0 (±7.2) for
the immediate release formulation. A difference was also
observed in the SG ratings with 0.90 (±0.05) and 0.86 (±0.07)
for the sustained release formulation and immediate release for-
mulation, respectively. These results were conﬁrmed by the val-
uations of the combination therapy health states. In general, the
ratings for monotherapy were given a higher valuation than com-
bination therapy. CONCLUSIONS: In this study, the health
states assumed equal effectiveness between a once-daily and a
three times daily preparation, in order to assess the utility dif-
ference resulting only from frequency of dosing. Participants
showed a preference for ADHD treatments with once daily
dosing.
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OBJECTIVES: Compare patient- and caregiver-reported out-
comes on 25 objective questions contained within the 51-item
Schizophrenia Outcomes Assessment Project (SOAP-51) quality
of life survey. METHODS: In total, 1500 community-residing
individuals with schizophrenia in ﬁve states (Massachusetts,
South Carolina, Wisconsin, Arizona, Washington) completed
SOAP-51 survey at baseline and weeks 4, 5, and 12. Previously,
factor analysis indicated SOAP-51 had eight factors (satisfaction,
self concept, work/role, mental health, interpersonal, medication
effects, activities of daily living, and physical function) with
Cronbach alphas ranging from 0.728–0.937 and test/retest intr-
aclass correlations >0.70 for all but one factor. An expert panel
identiﬁed 25 SOAP items that could be objectively measured.
This 25-item subset was given to each patient’s primary caregiver
concurrent with each patient’s SOAP-51 administration. Care-
givers were asked to answer each item in two ways: 1) What is
your objective response?, and 2) What do you think is the
patient’s response? Three correlation sets were performed for
week four responses: a) caregiver’s objective responses compared
to caregiver’s estimation of patient’s responses (Correlation A),
b) caregiver’s objective response compared to patient’s responses
(Correlation B); and caregiver’s estimation of patient’s responses
compared to patient’s responses (Correlation C). RESULTS:
Strongest correlations occurred in Correlation A [factor scores
for caregiver’s objective responses compared to caregiver’s esti-
mation of patient’s responses (0.534–0.862)]; lowest for Corre-
lation B [caregiver’s objective response compared to patient’s
responses (-0.292–0.367)]; and intermediate for Correlation C
[caregiver’s estimation of patient’s responses compared to
patient’s responses (-0.353–0.564)]. Physical function factor
correlations were the strongest in Correlation A (0.862), but the
lowest in Correlation B (-0.292) and C (-0.353). CONCLU-
SIONS: Caregiver objective assessments of individuals with
schizophrenia can vary markedly from patient-reported 
outcomes, but asking caregivers to view the world through the
eyes of the patient closes this gap. Asking caregivers to assume
a patient’s perspective may improve patient-caregiver 
communications.
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OBJECTIVES: Patient-reported outcomes such as health-related
quality of life (HRQL) are a frequent endpoint used in studies
of Major Depressive Disorder (MDD), but little is known if
results of these scales conducted during randomized clinical trials
(RCT’s) accurately reﬂect patients’ perceptions of the “real
world”. METHODS: An observational study and a randomized
double blind clinical trial with similar design, inclusion and
exclusion criteria and schedule of visits were used. These two
eight-week studies evaluated primary care MDD patients accord-
ing to the DSM-IV. Patients were asked to ﬁll in the EuroQoL
and the Quality of Life in Depression Scale (QLDS) at baseline
and eight weeks later, while physicians rated the severity of
